云鹏医药集团

Yunpeng Pharmaceutical Group is a comprehensive high-tech pharmaceutical enterprise integrating drug research and development, production, sales, and logistics. Founded in 1998 and headquartered in Shanxi Province, China, the company possesses over 200 drug approval numbers covering chemical drugs, traditional Chinese medicines, and active pharmaceutical ingredients (APIs). Its core product portfolio includes small molecule generics and APIs such as mexiletine hydrochloride, indometacin, vitamin u, and norfloxacin, which are distributed globally across markets like India, Japan, South Korea, and Russia. The group operates multiple GMP-certified production lines and established the Beijing Yunpeng Pengcheng Drug Research Institute in 2018 to advance its R&D capabilities and generic drug consistency evaluations. It maintains strategic partnerships with major domestic distributors and international CROs to support its commercial growth.